Form 4: Orgenesis Inc. Director Jagannathan Acquires Stock Options

Director Bhalaji Jagannathan of Orgenesis Inc. was granted stock options under the company's 2017 Equity Incentive Plan.

Summary

• Bhalaji Jagannathan, a director at Orgenesis Inc., has reported the acquisition of stock options.
• The options were granted under the company's 2017 Equity Incentive Plan.
• A total of 1,875 stock options were granted, with an exercise price of $0.98 per share.
• 625 options vest in three years, one third each year starting December 12, 2025, December 12, 2026, and December 12, 2027.
• 1,250 options vest in one year, beginning on December 12, 2024.
• The options expire on December 12, 2034.
• The vesting of the options is contingent on the director's continued service on the Board of Directors.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no indications of negative news or concerns.

Positives

• The granting of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Risks

• The value of the options is dependent on the future performance of Orgenesis Inc.'s stock price.
• The options will not vest if the director does not continue to serve on the Board of Directors.

Future Outlook

The director's future compensation is tied to the performance of the company's stock price.

Industry Context

Stock option grants are a common practice for incentivizing directors and aligning their interests with shareholders in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one to three years is typical for such grants, designed to encourage long-term commitment and performance.
• The exercise price of $0.98 is a fixed price at the time of the grant, and the value of the options will fluctuate with the market price of Orgenesis Inc. stock, similar to other companies like CRISPR Therapeutics or Editas Medicine.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's performance.
• The director is incentivized to contribute to the company's success to increase the value of their options.

Key Dates

Keywords

stock options, Orgenesis Inc., director, equity incentive plan, Bhalaji Jagannathan, vesting